{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:07:38Z","timestamp":1791940058162,"version":"4.3.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00280-021-04328-9","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T15:02:16Z","timestamp":1627398136000},"page":"805-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cetuximab-induced rash is associated with overall survival in patients with recurrent\/metastatic squamous cell carcinoma of head and neck"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-0444","authenticated-orcid":false,"given":"Sema Sezgin","family":"G\u00f6ksu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Murat","family":"Tatl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011flayan","family":"Geredeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Atc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Ayberk","family":"Besen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Mertsoylu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fckremin","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00d6zdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin G\u00f6kta\u015f","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Bilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Karaa\u011fa\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet Ali","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senar","family":"Ebin\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan \u015eenol","family":"Co\u015fkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"issue":"10","key":"4328_CR1","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s12325-018-0791-0","volume":"35","author":"G Fornasier","year":"2018","unstructured":"Fornasier G, Francescon S, Baldo P (2018) An update of efficacy and safety of cetuximab in metastatic colorectal cancer: a narrative review. Adv Ther 35(10):1497\u20131509. https:\/\/doi.org\/10.1007\/s12325-018-0791-0","journal-title":"Adv Ther"},{"issue":"11","key":"4328_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa0802656","journal-title":"N Engl J Med"},{"issue":"10212","key":"4328_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, Psyrri A, Bast\u00e9 N, Neupane P, Bratland \u00c5, Fuereder T, Hughes B, Mes\u00eda R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, Gonz\u00e1lez Mendoza R, Roy A, Zhang Y, KEYNOTE-048 Investigators (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London, England) 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet (London, England)"},{"issue":"1","key":"4328_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3816\/CCC.2008.n.007","volume":"7","author":"P Racca","year":"2008","unstructured":"Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, Milanesi E, Ciorba A, Paris M, Facilissimo I, Macrip\u00f2 G, Clerico M, Ciuffreda L (2008) Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic\/dermatologic cooperation. Clin Colorectal Cancer 7(1):48\u201354. https:\/\/doi.org\/10.3816\/CCC.2008.n.007","journal-title":"Clin Colorectal Cancer"},{"key":"4328_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/734249","volume":"2014","author":"K Chanprapaph","year":"2014","unstructured":"Chanprapaph K, Vachiramon V, Rattanakaemakorn P (2014) Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract 2014:734249. https:\/\/doi.org\/10.1155\/2014\/734249","journal-title":"Dermatol Res Pract"},{"issue":"1","key":"4328_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ijc.27654","volume":"132","author":"S Stintzing","year":"2013","unstructured":"Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 132(1):236\u2013245. https:\/\/doi.org\/10.1002\/ijc.27654","journal-title":"Int J Cancer"},{"issue":"3","key":"4328_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","volume":"8","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 8(3):173\u2013181. https:\/\/doi.org\/10.1007\/s11523-013-0257-x","journal-title":"Target Oncol"},{"issue":"1","key":"4328_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","volume":"11","author":"JA Bonner","year":"2010","unstructured":"Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(09)70311-0","journal-title":"Lancet Oncol"},{"issue":"5","key":"4328_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.ijrobp.2016.03.011","volume":"95","author":"V Bar-Ad","year":"2016","unstructured":"Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT (2016) Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: the RTOG experience. Int J Radiat Oncol Biol Phys 95(5):1346\u20131354. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.03.011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4328_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3389\/fonc.2018.00616","volume":"8","author":"S Uozumi","year":"2018","unstructured":"Uozumi S, Enokida T, Suzuki S, Nishizawa A, Kamata H, Okano T, Fujisawa T, Ueda Y, Okano S, Tahara M, Yamaguchi M (2018) Predictive value of cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and NECK. Front Oncol 8:616. https:\/\/doi.org\/10.3389\/fonc.2018.00616","journal-title":"Front Oncol"},{"issue":"4","key":"4328_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/11598190-000000000-00000","volume":"11","author":"L Wang","year":"2011","unstructured":"Wang L, Chen YZ, Shi D, Shi XY, Zou Z, Zhao JH (2011) Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis. Drugs R&D 11(4):317\u2013326. https:\/\/doi.org\/10.2165\/11598190-000000000-00000","journal-title":"Drugs R&D"},{"issue":"2","key":"4328_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.imlet.2004.08.012","volume":"96","author":"P Lewkowicz","year":"2005","unstructured":"Lewkowicz P, Tch\u00f3rzewski H, Dytnerska K, Banasik M, Lewkowicz N (2005) Epidermal growth factor enhances TNF-alpha-induced priming of human neutrophils. Immunol Lett 96(2):203\u2013210. https:\/\/doi.org\/10.1016\/j.imlet.2004.08.012","journal-title":"Immunol Lett"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04328-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04328-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04328-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T08:14:38Z","timestamp":1632989678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04328-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["4328"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04328-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest competing with the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study is approved by the Akdeniz University Clinical Trials Ethics Committee, approval date: 13\/01\/2021, approval number 32.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this was a retrospective, multicenter study; all centers got permissions from their institutions in accordance with local guides.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for data collection"}},{"value":"All authors agree with the submission.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}